IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates

IN8BIO, INC.

2024-Q3 EPS reported -$0.53

Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.
Cash $4.0M at Sept 30; closed Oct private placement for $11.6M net proceeds, extending runway into Q1 2026.
R&D $3.3M (-13% YoY), G&A $2.7M (-21% YoY); severance charges $1.1M from workforce reduction.
All AML patients in INB-100 remain in CR; FDA provided registrational path; expansion to ~25 patients planned.
Suspended INB-400 Phase 2 enrollment for newly diagnosed GBM; monitoring continues at SNO and ASH meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.